Oruka Therapeutics, Inc. (ORKA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
221 Crescent Street Building 23, Suite 105
Menlo Park, CA
United States of America (the)
Phone
203-554-7604
Website
Sector
Healthcare
Industry
Biotechnology
Employees
68
First IPO Date
August 08, 1997
| Name | Title | Pay | Year Born |
| Lawrence Otto Klein | President, Chief Executive Officer & Director | 1.08M | 1983 |
| Joana Goncalves | Chief Medical Officer | 730,980 | 1974 |
| Paul T. Quinlan | General Counsel & Secretary | 730,980 | 1963 |
| Christopher Finch | Senior VP and Head of Business Development & Strategy | 0 | N/A |
| Laura Sandler | Chief Operating Officer | 0 | 1978 |
| Rajiv Panwar | Senior VP and Head of Chemistry, Manufacturing & Controls | 0 | N/A |
| Arjun Agarwal | Senior Vice President of Finance & Treasurer | 0 | 1976 |
| Alan Lada | VP of IR & Capital Markets | 0 | N/A |
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.